Repurposing of dipeptidyl peptidase FDA-approved drugs in Alzheimer's disease using network pharmacology and in-silico approaches

Repurposing of dipeptidyl peptidase FDA-approved drugs in Alzheimer's disease using network pharmacology and in-silico approaches

Type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) have similar clinical characteristics in the brain and islet, as well as an increased incidence with ageing and familial susceptibility. Therefore, in recent years there has been a great desire for research that elucidates how anti-diabeti...

Full description

Bibliographic Details
Main Authors: Roney, Miah, Uddin, Md. Nazim, Khan, Azmat Ali, Fatima, Sabiha, Mohd Fadhlizil Fasihi, Mohd Aluwi, Hamim, S.M. Istiaque, Ahmad, Asrar
Format: Article
Language:English
Published: Elsevier Ltd 2025
Subjects:
RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
RM Therapeutics. Pharmacology
Online Access:https://umpir.ump.edu.my/id/eprint/45463/

Internet

https://umpir.ump.edu.my/id/eprint/45463/

Similar Items